Daily Respiratory Research Analysis
Analyzed 93 papers and selected 3 impactful papers.
Summary
Three impactful respiratory-focused studies stand out today: a multicenter randomized trial found that early in-bed cycling plus high-dose intravenous amino acids did not improve functional outcomes in acute respiratory failure; a systematic review and meta-analysis showed that using a single GeneXpert MTB/RIF test can shorten airborne isolation by ~39 hours versus serial sputum smears; and a secondary analysis of the EDEN ARDS trial identified pre-intervention GIP as a biomarker predicting benefit from trophic enteral feeds.
Research Themes
- ICU rehabilitation and nutrition in acute respiratory failure
- Rapid diagnostics to optimize infection control
- Precision nutrition and biomarker-driven ARDS care
Selected Articles
1. Nutrition and Exercise in Critical Illness (NEXIS) trial: randomized trial of combined in-bed cycling and intravenous amino acid plus usual care.
In a multicenter phase 2 RCT of 115 ICU patients with acute respiratory failure, protocolized early in-bed cycling plus high-protein intravenous amino acids did not improve 6-minute walk distance at hospital discharge versus usual care, nor secondary outcomes up to 6 months. The intervention was feasible and appeared safe but was stopped early for slow recruitment.
Impact: This rigorous negative trial challenges assumptions that combining early mobilization with augmented protein delivery improves functional recovery in ICU respiratory failure, guiding resource allocation and protocol design.
Clinical Implications: Routine addition of in-bed cycling and high-dose amino acids to usual care for ARF should not be expected to improve short-term functional outcomes; programs should prioritize interventions with demonstrated benefit and consider targeted enrollment and dose-response questions in future trials.
Key Findings
- Early in-bed cycling (mean 40±7 min/day) plus intravenous amino acids (total protein ~1.9 g/kg/day) did not improve 6MWD at discharge versus usual care (median 108 m vs 95 m; P=0.51).
- Secondary functional outcomes at ICU and hospital discharge, and 6-month follow-up measures, were similar between groups.
- The combined intervention appeared safe, but the trial was stopped early due to slow recruitment, yielding 115 randomized patients.
Methodological Strengths
- Randomized, multicenter design with blinded primary outcome assessment (6MWD).
- Intention-to-treat analysis with protocolized delivery of exercise and protein targets.
Limitations
- Early termination for slow recruitment led to reduced power and potential type II error.
- Phase 2 design; dosing, timing, and patient selection may not have been optimal to detect benefit.
Future Directions: Investigate patient subgroups most likely to benefit, optimize exercise dose and protein targets, and test pragmatic protocols integrating mobility and nutrition with sufficient power and adherence metrics.
RATIONALE: Patients with acute respiratory failure (ARF) in intensive care units (ICUs) often experience immobility and limited nutritional intake, with long-lasting impairments. OBJECTIVE: Evaluate whether combined in-bed cycling exercise and intravenous amino acid, initiated early in the ICU, improves physical functioning. METHODS: This multicenter phase 2 trial randomly allocated patients 1:1 to protocolized in-bed cycling (45 min/d) plus intravenous amino acid (total protein intake: 2.0-2.5 g/kg/d) plus usual care vs usual care alone. Blinded assessment of 6-minute walk distance (6MWD) at hospital discharge was the primary outcome. Secondary outcomes included functional measures at ICU and hospital discharge, along with phone surveys at the 6-month follow-up. Patients were analyzed according to intention to treat. The planned sample size was 128 evaluable patients (64 per arm). MEASUREMENTS AND MAIN RESULTS: In total, 115 patients (median age ∼55 years, 55% male, Acute Physiology and Chronic Health Evaluation II ∼24, >90% mechanically ventilated) were randomized (60 intervention; 55 control). Enrollment was stopped early due to slow recruitment, with no evidence of safety concerns. The mean duration of cycling was 40 ± 7 min/d (control: 0 min/d), with total protein intake of 1.9 ± 0.6 g/kg/d (control: 0.9 ± 0.6). The median (interquartile range) 6MWD was similar between intervention and control: 108 (15-242) and 95 (0-196) m (P = .51) (median difference, 10; 95% CI, -75 to 84). Secondary outcomes were also similar between groups. CONCLUSION: Among patients with ARF, a combined intervention of early in-bed cycling and amino acid supplementation appeared safe but did not improve 6MWD or secondary outcomes during hospitalization or 6-month follow-up. Clinicaltrials.gov (NCT03021902).
2. The impact on airborne isolation duration utilizing GeneXpert versus acid-fast bacilli smears to guide discontinuation among individuals with suspected pulmonary tuberculosis: a systematic review and meta-analysis.
Across five studies (n=1,409), using a single unconcentrated GeneXpert test to guide de-isolation shortened airborne isolation by a pooled median of 38.8 hours versus serial AFB smears, without compromising diagnostic performance. Findings support GeneXpert-based protocols to reduce isolation time and resource utilization in low-incidence TB settings.
Impact: This synthesis provides quantitative evidence for policy change in hospital infection control workflows, with immediate operational value in optimizing isolation resources and patient flow.
Clinical Implications: Hospitals can safely adopt GeneXpert-based de-isolation strategies to reduce isolation duration, improve bed turnover, and lower costs, while maintaining diagnostic accuracy; local incidence and lab workflows should guide implementation.
Key Findings
- Meta-analysis of five studies (n=1,409) showed a pooled 38.8-hour reduction in median isolation time with a single unconcentrated GeneXpert versus serial AFB smears.
- All included studies were in low-incidence TB settings, supporting generalizability to similar health systems.
- Diagnostic accuracy and length of stay were assessed as secondary outcomes; GeneXpert did not adversely affect diagnostic performance.
Methodological Strengths
- PROSPERO-registered systematic review with predefined methods and multi-database search.
- Use of median-based quantile estimation to synthesize time-to-event distributions across heterogeneous studies.
Limitations
- Heterogeneity in study designs and de-isolation protocols; predominance of low-incidence settings may limit applicability elsewhere.
- Limited number of studies and potential publication bias; patient-level covariates were not uniformly available.
Future Directions: Prospective implementation studies comparing GeneXpert-based versus smear-based de-isolation in varied incidence settings, including cost-effectiveness, nosocomial transmission, and equity impacts.
OBJECTIVE: The GeneXpert® MTB/RIF nucleic acid amplification test has been proposed as an alternative method to smear microscopy in guiding de-isolation for patients with suspected pulmonary tuberculosis, given its convenience and higher diagnostic accuracy. Currently, there is no comprehensive review summarizing the evidence on the isolation duration using GeneXpert. This systematic review and meta-analysis addressed the length of airborne infection isolation in hospitalized patients initially suspected of having pulmonary tuberculosis where de-isolation decisions were guided by GeneXpert nucleic acid amplification test compared to traditional smear microscopy. METHODS: We conducted a comprehensive search in databases (Medline, Embase, and Scopus) from January 1, 2001, to April 1, 2026, and applied median-based quantile estimation methods to determine the pooled difference in median times of isolation. We also assessed diagnostic accuracy as well as hospital length of stay as secondary outcomes. RESULTS: We screened 746 titles and abstracts, of which 7 were eligible for inclusion. Five studies included in the meta-analysis involved 1,409 patients, all within low-incidence tuberculosis settings. The meta-analysis demonstrated that use of a single unconcentrated GeneXpert versus serial acid-fast bacilli smear microscopy resulted in a pooled reduction in median isolation duration by 38.8 hours (95% confidence interval 20.2-57.3 hours). CONCLUSION: Compared to serial microscopy, GeneXpert done on a single unconcentrated respiratory specimen reduces airborne infection isolation duration by over 1.5 days, on average, making it an attractive strategy for optimizing healthcare facility resources while evaluating persons for pulmonary tuberculosis.Protocol Registration (PROSPERO, CRD42024538644).
3. Incretins Predict Response to Enteral Nutrition Strategies in the EDEN Trial: A Secondary Analysis.
In a pre-specified secondary analysis of 889 EDEN participants, higher pre-intervention GIP levels identified ARDS patients who had lower 60-day mortality with trophic versus full enteral feeding, while GLP-1 and ARDS subphenotypes did not predict heterogeneity of treatment effect. GIP may guide precision nutrition strategies in ARDS, pending validation.
Impact: This study advances precision critical care by proposing a readily measurable biomarker (GIP) to personalize enteral nutrition intensity in ARDS, addressing prior neutral trial results through heterogeneity of treatment effect.
Clinical Implications: If validated, baseline GIP could stratify ARDS patients to trophic versus full feeding strategies to reduce mortality, integrating biomarker-guided nutrition into ICU workflows.
Key Findings
- Among 889 ARDS patients, those in the highest GIP tertile had lower 60-day mortality with trophic feeds versus full feeds (14.1% vs 27.2%).
- Adjusted interaction between treatment assignment and GIP predicted heterogeneity of treatment effect (interaction p=0.01).
- GLP-1 levels, ARDS subphenotypes, and baseline mortality risk did not predict differential response to nutrition strategy.
Methodological Strengths
- Pre-intervention biomarker measurement and adjusted interaction analyses for HTE.
- Large sample from an RCT framework (EDEN), enabling rigorous subgroup evaluation.
Limitations
- Secondary analysis with potential for residual confounding and multiple testing concerns.
- Findings are hypothesis-generating and require prospective validation before clinical implementation.
Future Directions: Prospective trials stratifying ARDS patients by baseline GIP to test trophic versus full feeding; mechanistic studies on enteroendocrine signaling in critical illness.
RATIONALE: The Early versus Delayed Enteral Nutrition (EDEN) trial found no significant difference in mortality between trophic and full enteral nutrition strategies in acute respiratory distress syndrome (ARDS) patients. Heterogeneity of treatment effect (HTE) has been identified in prior ARDS trials. We previously identified intestine-derived incretin hormones (glucose-dependent insulinotropic peptide [GIP] and glucagon-like peptide [GLP]-1 as potential predictive biomarkers in the response to nutrition. OBJECTIVES: To investigate incretins as biomarkers predictive of HTE in EDEN. METHODS: GIP, GLP-1, and host immune response biomarkers were measured from pre-intervention EDEN plasma samples. We investigated HTE with 60-day mortality as a primary outcome by testing interaction of treatment with circulating incretin levels in analyses adjusted for demographics, severity of illness, diabetes mellitus, and circulating interleukin-6, and assessed mortality by treatment arm across incretin tertiles. We additionally tested for HTE by de novo ARDS subphenotypes and by risk of mortality. MEASUREMENTS & MAIN RESULTS: 889 participants were included (452 randomized to trophic and 437 to full enteral nutrition). GIP predicted HTE to enteral nutrition strategies (adjusted interaction p-value 0.01) with lower mortality from trophic feeds (14.1% vs 27.2% in full) in patients in the highest GIP tertile but similar mortality in other tertiles. GLP-1, ARDS subphenotypes, and baseline risk of mortality did not predict HTE. CONCLUSIONS: GIP was unique among incretins in predicting HTE to enteral nutrition strategies in EDEN. Further studies are needed to validate our findings as GIP might serve as a biomarker to guide level of enteral nutrition for ARDS patients.